tetano
Editor, Senior Moderator
BMC Neurol
. 2021 Mar 23;21(1):135.
doi: 10.1186/s12883-021-02162-3.
Concomitant Guillain-Barre syndrome with COVID-19: a case report
Nuvia Mackenzie[SUP] 1 [/SUP], Eva Lopez-Coronel[SUP] 1 [/SUP], Alberto Dau[SUP] 1 [/SUP], Dieb Maloof[SUP] 1 [/SUP], Salvador Mattar[SUP] 1 [/SUP], Jesus Tapia Garcia[SUP] 1 [/SUP], Briyis Fontecha[SUP] 1 [/SUP], Cristina M Lanata[SUP] 2 [/SUP], Hernan Felipe Guillen-Burgos[SUP] 3 4 [/SUP]
Affiliations
Abstract
Background: During the Coronavirus disease 2019 (COVID-19) pandemic, different neurological manifestations have been observed. However, only a few cases of Guillain-Barre syndrome (GBS) and COVID-19 have been reported. Therefore, the aim of this study is to investigate a case of concomitant GBS with COVID-19 in Colombia.
Case presentation: A 39-year-old woman was admitted to a teaching hospital in Barranquilla, Colombia with a history of progressive general weakness with lower limb dominance. Previous symptoms such as ageusia, anosmia and intense headache were reported. Upon admission, facial diplegia, quadriparesis with lower extremity predominance and Medical Research Council muscular strength of 2/5 in the lower limbs and 4/5 in the upper limbs were reported. During clinical evolution, due to general areflexia, hypertensive emergency and progressive diaphragmatic weakness, the patient was admitted to an intensive care unit. The cerebrospinal fluid analysis showed protein-cytological dissociation and the GBS diagnosis was confirmed via a nerve conduction and electromyography test. With regard to the symptoms before hospitalisation, SARS-CoV-2 diagnostic testing was performed with positive results in the second test. The patient was managed with supportive care and was discharged after 20 days of hospitalization with clinical improvement.
Conclusions: Only a few cases of COVID-19 with GBS have been reported. Different subtypes have been previously identified, such as Miller-Fisher syndrome and dysautonomic GBS with SARS-CoV-2 infection. This study investigated the first confirmed case of COVID-19 with concomitant GBS in Colombia. In patients with GBS, several viral and bacterial pathogens have been found in case-control studies but the factors that induce the immune-mediated destruction of the nerve tissues have not been determined. Further studies are needed to determine the possible association between COVID-19 exposure and GBS.
Keywords: COVID-19; Case report; Guillain-Barre syndrome; SARS-CoV-2.
. 2021 Mar 23;21(1):135.
doi: 10.1186/s12883-021-02162-3.
Concomitant Guillain-Barre syndrome with COVID-19: a case report
Nuvia Mackenzie[SUP] 1 [/SUP], Eva Lopez-Coronel[SUP] 1 [/SUP], Alberto Dau[SUP] 1 [/SUP], Dieb Maloof[SUP] 1 [/SUP], Salvador Mattar[SUP] 1 [/SUP], Jesus Tapia Garcia[SUP] 1 [/SUP], Briyis Fontecha[SUP] 1 [/SUP], Cristina M Lanata[SUP] 2 [/SUP], Hernan Felipe Guillen-Burgos[SUP] 3 4 [/SUP]
Affiliations
- PMID: 33757457
- DOI: 10.1186/s12883-021-02162-3
Abstract
Background: During the Coronavirus disease 2019 (COVID-19) pandemic, different neurological manifestations have been observed. However, only a few cases of Guillain-Barre syndrome (GBS) and COVID-19 have been reported. Therefore, the aim of this study is to investigate a case of concomitant GBS with COVID-19 in Colombia.
Case presentation: A 39-year-old woman was admitted to a teaching hospital in Barranquilla, Colombia with a history of progressive general weakness with lower limb dominance. Previous symptoms such as ageusia, anosmia and intense headache were reported. Upon admission, facial diplegia, quadriparesis with lower extremity predominance and Medical Research Council muscular strength of 2/5 in the lower limbs and 4/5 in the upper limbs were reported. During clinical evolution, due to general areflexia, hypertensive emergency and progressive diaphragmatic weakness, the patient was admitted to an intensive care unit. The cerebrospinal fluid analysis showed protein-cytological dissociation and the GBS diagnosis was confirmed via a nerve conduction and electromyography test. With regard to the symptoms before hospitalisation, SARS-CoV-2 diagnostic testing was performed with positive results in the second test. The patient was managed with supportive care and was discharged after 20 days of hospitalization with clinical improvement.
Conclusions: Only a few cases of COVID-19 with GBS have been reported. Different subtypes have been previously identified, such as Miller-Fisher syndrome and dysautonomic GBS with SARS-CoV-2 infection. This study investigated the first confirmed case of COVID-19 with concomitant GBS in Colombia. In patients with GBS, several viral and bacterial pathogens have been found in case-control studies but the factors that induce the immune-mediated destruction of the nerve tissues have not been determined. Further studies are needed to determine the possible association between COVID-19 exposure and GBS.
Keywords: COVID-19; Case report; Guillain-Barre syndrome; SARS-CoV-2.